Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro-Oncology. 2021;23(6):894–904.

Article  PubMed  Google Scholar 

Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol. 2015;4:33.

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Zhang C, Zhang J, Kong L, Zhu H, Yu J. The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. Oncotarget. 2017;8(16):26368–79.

Article  PubMed  Google Scholar 

Lopes S, Vieira I, Abreu M, Pousa I, Ferreira A, Sousa S, et al. Prognostic factors and survival according to tumor subtype in women with breast cancer brain metastases. Curr Probl Cancer. 2022;46(6):100866.

Article  PubMed  Google Scholar 

Bailleux C, Eberst L, Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer. 2021;124(1):142–55.

Article  PubMed  Google Scholar 

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.

Article  CAS  PubMed  Google Scholar 

Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65–72.

Article  PubMed  Google Scholar 

Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019;121(12):991–1000.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244–8.

Article  CAS  PubMed  Google Scholar 

Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45.

Article  PubMed  Google Scholar 

Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012;136(1):153–60.

Article  PubMed  Google Scholar 

Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, et al. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010;21(12):2348–55.

Article  CAS  PubMed  Google Scholar 

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):2111–7.

Article  PubMed  Google Scholar 

Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008;10(1):R20.

Article  PubMed  PubMed Central  Google Scholar 

Cho E, Rubinstein L, Stevenson P, Gooley T, Philips M, Halasz LM, et al. The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most? Breast Cancer Res Treat. 2015;149(3):743–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510–4.

Article  PubMed  Google Scholar 

Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017;17(1):23–8.

Article  PubMed  Google Scholar 

Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26–41.

Article  CAS  PubMed  Google Scholar 

Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology. 2020;22(9):1359–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neuro-Oncol. 2006;78(3):255–60.

Article  CAS  Google Scholar 

Cocconi G, Lottici R, Bisagni G, Bacchi M, Tonato M, Passalacqua R, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Investig. 1990;8(3-4):327–34.

Article  CAS  Google Scholar 

Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85(7):1599–605.

Article  CAS  PubMed  Google Scholar 

Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, et al. Taiwan Breast Cancer Consortium. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res. 2015;21(8):1851–8.

Article  CAS  PubMed  Google Scholar 

Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res. 1994;54(19):5118–22.

CAS  PubMed  Google Scholar 

Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol. 1996;37(3):195–202.

Article  CAS  PubMed  Google Scholar 

Oberhoff C, Kieback DG, Wurstlein R, Deertz H, Sehouli J, van Soest C, et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie. 2001;24(3):256–60.

CAS  PubMed  Google Scholar 

Kocher M, Eich HT, Semrau R, Guner SA, Muller RP. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther Onkol. 2005;181(1):20–5.

Article  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

Article  CAS  PubMed  Google Scholar 

Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neuro-Oncol. 2001;53(3):259–65.

Article  CAS  Google Scholar 

Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 2001;12(2):249–54.

Article  CAS  PubMed  Google Scholar 

Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348–54.

Article  CAS  PubMed  Google Scholar 

Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neuro-Oncol. 2005;71(1):61–5.

Article  CAS  Google Scholar 

Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neuro-Oncol. 2007;85(2):223–7.

Article  CAS  Google Scholar 

Morabito A, Longo R, Gattuso D, Carillio G, Massaccesi C, Mariani L, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep. 2006;16(2):393–8.

CAS  PubMed  Google Scholar 

Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, et al. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neuro-Oncol. 2008;87(1):85–90.

Article  CAS  Google Scholar